These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20586686)

  • 1. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults.
    Citrome L
    Expert Rev Neurother; 2010 Jul; 10(7):1031-7. PubMed ID: 20586686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
    Vieta E; Suppes T; Eggens I; Persson I; Paulsson B; Brecher M
    J Affect Disord; 2008 Aug; 109(3):251-63. PubMed ID: 18579216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission.
    Ketter TA; Agid O; Kapur S; Loebel A; Siu CO; Romano SJ
    J Psychiatr Res; 2010 Jan; 44(1):8-14. PubMed ID: 19699488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E; Ramey T; Keller D; English PA; Loebel AD; Miceli J
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive oral ziprasidone in patients with acute mania treated with lithium or divalproex, part 1: results of a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Vanderburg DG; Karayal ON; Kolluri S; Bachinsky M; Cavus I
    J Clin Psychiatry; 2012 Nov; 73(11):1412-9. PubMed ID: 23218157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olanzapine: new indication. Prevention of bipolar disorder: unconvincing trials.
    Prescrire Int; 2005 Aug; 14(78):140-2. PubMed ID: 16106596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study).
    Weisler RH; Nolen WA; Neijber A; Hellqvist A; Paulsson B;
    J Clin Psychiatry; 2011 Nov; 72(11):1452-64. PubMed ID: 22054050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.
    Yatham LN
    J Affect Disord; 2011 Jan; 128 Suppl 1():S21-8. PubMed ID: 21220077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
    Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
    Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study.
    Nery FG; Monkul ES; Hatch JP; Fonseca M; Zunta-Soares GB; Frey BN; Bowden CL; Soares JC
    Hum Psychopharmacol; 2008 Mar; 23(2):87-94. PubMed ID: 18172906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziprasidone monotherapy in bipolar II depression: an open trial.
    Liebowitz MR; Salmán E; Mech A; Dunner D; Johnson AE; Akhtar J; Pratap R
    J Affect Disord; 2009 Nov; 118(1-3):205-8. PubMed ID: 19264363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing relapse prevention in bipolar disorder with adjunctive ziprasidone: clinical and methodological implications.
    Bowden CL; Karayal ON; Schwartz JH; Gundapaneni BK; O'Gorman C
    J Affect Disord; 2013 Jan; 144(1-2):171-5. PubMed ID: 22999893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.
    Salloum IM; Cornelius JR; Daley DC; Kirisci L; Himmelhoch JM; Thase ME
    Arch Gen Psychiatry; 2005 Jan; 62(1):37-45. PubMed ID: 15630071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?
    Lombardo I; Sachs G; Kolluri S; Kremer C; Yang R
    J Clin Psychopharmacol; 2012 Aug; 32(4):470-8. PubMed ID: 22722504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
    McIntyre RS
    Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients.
    Wang PW; Hill SJ; Childers ME; Chandler RA; Rasgon NL; Ketter TA
    J Psychiatr Res; 2011 Aug; 45(8):1128-32. PubMed ID: 21371718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ziprasidone: efficacy and safety in patients with bipolar disorder.
    Patel NC; Keck PE
    Expert Rev Neurother; 2006 Aug; 6(8):1129-38. PubMed ID: 16893341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.